Skip to main content

Hims & Hers Health, Inc.

corporate_fare Company Profile

Hims & Hers Health, Inc.

HIMS·NYSE·Consumer Defensive·CIK 0001773751

Hims & Hers Health, Inc., launched in 2017, operates a consumer-focused platform that helps customers meet their health and wellness needs. The company provides a digital platform that includes access to a network of qualified healthcare providers, an electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization features. This platform enables access to treatments for various chronic conditions, such as sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, along with services like comprehensive laboratory testing. Hims & Hers connects patients with licensed healthcare professionals who can prescribe medications, including through personalized treatment plans, with prescriptions fulfilled online by licensed pharmacies. Additionally, the company offers a selection of non-prescription health and wellness products. Through its mobile applications, consumers can access educational programs, wellness content, community support, and other services. Since its founding, Hims & Hers has facilitated over fifty million telehealth consultations, providing access to care in the United States, Canada, the United Kingdom, and the European Union (specifically in Germany, the Republic of Ireland, France, and Spain). The company's strategy focuses on its brand, products and services, technology, and clinical excellence.

Hims & Hers Health, Inc. (NYSE:HIMS) is a publicly traded company in the Consumer Defensive sector. Wiseek monitors HIMS SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Hims & Hers Prices Upsized $350M Convertible Notes at 32.5% Premium for Growth
  • Hims & Hers Prices Upsized $350M Convertible Notes for Global Expansion, AI Investment
  • Hims & Hers Health Plans $300M Convertible Notes Offering for Global Expansion, AI
  • Surprise Q1 Loss Sends Hims & Hers Down 16% as Branded Weight-Loss Drug Pivot Hits Margins
  • Hims & Hers Reports Q1 Net Loss, Lower EBITDA Amid Restructuring & Legal Accruals

monitoring Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.35B
Net Income
$128.37M
Diluted EPS
$0.51
Op. Cash Flow
$300.01M
Free Cash Flow
$57.41M
Gross Profit
$1.73B
Operating Income
$105.61M
Cash & Equivalents
$228.62M
Total Debt
$972.58M
Debt / Equity
1.80×
Net Margin
5.5%
Shares Outstanding
224.96M sh
Source: 10-K · filed 2026-02-23 · accession 0001773751-26-000022

supervised_user_circle Insider Transactions

$127.47M sold
Net $127.47M selling · 100 transactions by 8 insiders · last 12 months
  • 2026-05-18 Okupe Oluyemi Chief Financial Officer Officer
    Open-market sale 7.95K sh $187.92K @ $23.64
  • 2026-04-20 Boughton Soleil Chief Legal Officer Officer
    Open-market sale 9.46K sh $283.89K @ $30.00
  • 2026-04-20 Okupe Oluyemi Chief Financial Officer Officer
    Open-market sale 19.64K sh $588.62K @ $29.96
  • 2026-04-17 Okupe Oluyemi Chief Financial Officer Officer
    Open-market sale 18K sh $501.16K @ $27.83
  • 2026-04-16 Okupe Oluyemi Chief Financial Officer Officer
    Open-market sale 36.92K sh $956.15K @ $25.90
  • 2026-04-06 Okupe Oluyemi Chief Financial Officer Officer
    Open-market sale 3.98K sh $79.41K @ $19.98
  • 2026-03-20 Okupe Oluyemi Chief Financial Officer Officer
    Open-market sale 9.22K sh $219.07K @ $23.77
  • 2026-03-17 Boughton Soleil Chief Legal Officer Officer
    Open-market sale 4.81K sh $118.81K @ $24.69
  • 2026-03-17 Becklund Irene PAO Officer
    Open-market sale 5.53K sh $136.51K @ $24.69
  • 2026-05-18 Okupe Oluyemi Chief Financial Officer Officer
    Option exercise 7.95K sh derivative
  • 2026-05-18 Okupe Oluyemi Chief Financial Officer Officer
    Option exercise 7.95K sh $39.83K @ $5.01
  • 2026-04-20 Okupe Oluyemi Chief Financial Officer Officer
    Option exercise 12.55K sh 2 fills derivative
  • 2026-04-20 Okupe Oluyemi Chief Financial Officer Officer
    Option exercise 12.55K sh $108.53K 2 fills, avg $8.65
  • 2026-04-17 Okupe Oluyemi Chief Financial Officer Officer
    Option exercise 6.18K sh $30.98K @ $5.01
  • 2026-04-17 Okupe Oluyemi Chief Financial Officer Officer
    Option exercise 6.18K sh derivative
  • 2026-04-06 Okupe Oluyemi Chief Financial Officer Officer
    Option exercise 3.98K sh derivative
  • 2026-04-06 Okupe Oluyemi Chief Financial Officer Officer
    Option exercise 3.98K sh $19.91K @ $5.01
  • 2026-03-20 Okupe Oluyemi Chief Financial Officer Officer
    Option exercise 4.49K sh derivative
  • 2026-03-20 Okupe Oluyemi Chief Financial Officer Officer
    Option exercise 4.49K sh $22.49K @ $5.01
  • 2026-04-09 Dudum Andrew Chief Executive Officer Officer · Director · 10% Owner
    Gift 845.87K sh 2 fills
From SEC Form 4 + 5 (insider beneficial-ownership filings) · last 12 months · view all on SEC EDGAR ↑
$23.02 -0.02% today
52-week range $13.74 – $70.43
Market cap
$5.25B
Volume
16.6M (0.5× avg)
3-mo avg 31.7M
Price snapshot as of 2026-05-20 21:44 UTC (Market snapshot (POST))

show_chartPrice Chart

Loading chart...

feed HIMS - Latest Insights

HIMS
May 19, 2026, 8:17 AM EDT
Filing Type: 8-K
Importance Score:
8
HIMS
May 19, 2026, 12:08 AM EDT
Source: Reuters
Importance Score:
8
HIMS
May 18, 2026, 7:17 AM EDT
Source: Reuters
Importance Score:
8
HIMS
May 12, 2026, 7:28 AM EDT
Source: Reuters
Importance Score:
8
HIMS
May 11, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
HIMS
May 11, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
8
HIMS
May 11, 2026, 4:06 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
HIMS
Apr 28, 2026, 8:23 AM EDT
Filing Type: DEF 14A
Importance Score:
7
HIMS
Apr 22, 2026, 11:22 AM EDT
Source: Reuters
Importance Score:
8
HIMS
Apr 16, 2026, 11:31 AM EDT
Source: Reuters
Importance Score:
8
HIMS
Apr 02, 2026, 5:28 PM EDT
Source: Reuters
Importance Score:
8
HIMS
Mar 27, 2026, 4:04 PM EDT
Source: Wiseek News
Importance Score:
8
HIMS
Mar 11, 2026, 5:21 PM EDT
Filing Type: 8-K
Importance Score:
9
HIMS
Mar 11, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
9
HIMS
Mar 09, 2026, 7:43 AM EDT
Source: ShareCast
Importance Score:
9
HIMS
Mar 03, 2026, 10:33 AM EST
Source: Reuters
Importance Score:
8
HIMS
Feb 23, 2026, 5:20 PM EST
Filing Type: 10-K
Importance Score:
9
HIMS
Feb 23, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
HIMS
Feb 19, 2026, 6:19 AM EST
Filing Type: 8-K
Importance Score:
9